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Vasoactive intestinal peptide (VIP) mediated inhibition of platelet aggregation has 
been demonstrated in rabbit platelets.’ While the mechanism by which VIP inhibits 
aggregation is thought to be via a specific receptor linked to adenylate cyclase, platelet 
receptors for VIP have not yet been demonstrated. The current studies were designed 
to test whether VIP regulates aggregation in human platelets and to determine whether 
specific, high-affinity VIP receptors are expressed on platelet membranes. 
MATERIALS AND METHODS 
Membrane Preparation 
Platelet-rich plasma was isolated from peripheral blood of normal human subjects. 
Platelets were disrupted in lysis buffer (10 mM Tris, 5 mM EDTA, pH 7.4) with a 
polytron. Plasma membranes were isolated by differential centrifugation’ and stored 
in Buffer A (20 mM Hepes, 150 m M  NaCl, 2 mM MgCl,, 5 m M  EDTA, 1 mM-& 
mercaptoethanol, 5 0  pg/ml phenylmethyl sulfonyl fluoride, pH 7.4). 
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[''-'I]VIP Binding Studies 
Membranes (200 pg protein) were incubated at 17'C with 100-150 pM [ 1*51]VIP 
(SA = 647 Ci/g), in the absence or presence of competing unlabeled peptide, in a 
final volume 0.5 ml. Membrane-bound [ "'IIVIP was separated from free by filtration 
through Whatman GF/C filters presoaked in 0.3% polyethylenimine as described by 
O'Dorisio et al. ' Time course and temperature studies demonstrated steady-state 
binding from 30 to 90 minutes at 17°C. The percentage of total counts bound to 
membrane protein ranged from 18% to 31% with 61% to 82% of bound ligand 
representing specific binding. Specific binding increased linearly with increasing con- 
centration (50 to 500 pg) of membrane protein. Kinetic parameters were determined 
by a nonlinear computer-assisted fit of the competitive binding data.' 
Platelet Aggregation Studies 
Peripheral blood was obtained from healthy volunteers and slowly dispensed into 
5-ml polystyrene tubes containing citrate (4.5 ml blood + 0.5 ml citrate). Platelet- 
rich plasma was prepared by centrifuging citrated blood at 25°C for six minutes at 
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FIGURE 1. Competitive binding of [ 1251]VIP to platelet membranes. 200 pg of membrane 
protein was incubated with 100 pM [ "'I]VIP in the presence of indicated concentrations of 
unlabeled VIP for 45 minutes at 17°C. Computer-assisted fit of 12 competitive binding experiments 
was used to calculate affinity constants (K,) and maximum number of binding sites (B-). 
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TABLE 1. Effect of VIP on Platelet Aggregation" 
Agent Percent Transmission 
ADP 
ADP + VIP 
PAF 
PAF + VIP 
80.5 t 7 
83.2 t 5 
75.8 2 4.1 
38.1 * 2 
VIP-mediated inhibition of platelet aggregation using platelet-rich plasma from three healthy 
volunteers. Platelets were stirred in siliconized glass cuvettes for 60 seconds in the presence or 
absence of 1 pLM VIP before addition of PAF or ADP. Values are mean f SD for three 
experiments. 
minutes at 1500 x g. Aliquots of platelet-rich plasma were stirred in siliconized glass 
cuvettes in a Bio/Data platelet aggregation profiler, Model PAP-3. PAF (l-alkyl-2- 
acetyl-glycero-3-phosphorylcholine) was purchased from Sigma and dissolved in mod- 
ified Tyrode's solution5 containing 5 mg/ml bovine serum albumin. VIP was dissolved 
in Tyrode's solution containing 0.5% BSA and 0.005% bacitracin. Platelet-rich plasma 
was incubated 60 seconds with or without VIP before addition of PAF or ADP. 
RESULTS AND CONCLUSIONS 
The specific binding (total bound [ 'zsI]VIP minus label bound in the presence of 
1 pM unlabeled VIP) increased linearly with membrane protein concentration. Com- 
puter analysis of the data from 12 separate experiments demonstrated a single class 
of high-affinity binding sites with a mean dissociation constant (K,) of 23 2 6.3 nM 
(FIG. 1). PHI, glucagon, and GHRF competed less effectively for ["'IIVIP binding 
sites, exhibiting K,s of 254 2 51, 441 k 21 and 135 k 73 nM, respectively. 
VIP effects on platelet aggregation were investigated as shown in TABLE 1. VIP 
inhibited PAF-induced platelet aggregation by 50%. PAF is a potent platelet aggre- 
gating agent: This phospholipid has been shown to inhibit cyclic AMP accumulation 
in intact platelets and to inhibit adenylate cyclase activity in membranes of rabbit and 
human platelets.' VIP stimulates adenylate cyclase in intact platelets' and thus VIP- 
mediated inhibition of PAF-induced platelet aggregation may result from the opposing 
effects of VIP and PAF on adenylate cyclase. 
In summary, platelet membranes have been shown to possess receptors for vas- 
oactive intestinal polypeptide (VIP). Competitive binding experiments using 200 pg 
membrane protein demonstrated a K, of 23 k 6.3 nM for [ 1251]VIP with a B,,, of 
3.9 2 1.1 nM. The binding of [ "'I]VIP to platelet membranes is highly specific; the 
homologous peptides, PHI, GHRF, and glucagon, have lower affinity than VIP. VIP 
antagonizes platelet aggregation induced by platelet-activating factor, but not ADP- 
induced aggregation. These results suggest that human platelets possess functional 
VIP receptors that modulate platelet aggregation. 
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